Pfizer and AstraZeneca Strike Global Agreement for OTC Version of Nexium®
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 8 (Table of Contents)
Published: 20 Aug-2012
DOI: 10.3833/pdr.v2012.i8.1791 ISSN: 1756-7874
Section: Distribution & Marketing
Fulltext:
Abstract
Pfizer has gained global rights to market an OTC version of AstraZeneca's blockbuster heartburn drug Nexium® (esomeprazole magnesium) for US$250 M upfront plus milestones and royalties...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018